Target intelligence / Profile preview

Chromosome 22 open reading frame 23 (C22orf23)

Target
C22orf23
Molecular classification
Other (intracellular protein, no evidence as receptor, enzyme, transporter, channel, etc.)
01

Overview

Chromosome 22 open reading frame 23 (C22orf23) is a human protein encoded by the C22orf23 gene located at 22q13.1, spanning 10,620 base pairs. The protein is 217 amino acids in length, predicted to be a globular, intracellular protein without known transmembrane domains, primarily located in the nucleus. It is expressed in many tissues, with the highest levels in the testes, but also detected at low levels in the brain, kidney, stomach, skin, thyroid, urinary bladder, and reproductive organs. Functional studies primarily suggest a role in protein binding, and several protein–protein interactions are predicted, including interactions with cyclin-D1-binding protein 1 (cell cycle regulation), vacuolar protein sorting-associated protein 28, and estrogen related receptor gamma. C22orf23 has no known paralogs but is evolutionarily conserved across vertebrates and some invertebrates and fungi, indicating a conserved biological function. Disease associations are limited and largely correlative, with some studies linking mutations or altered expression to cancers (eg, breast cancer), demyelinating disorders, Waardenburg syndrome, cardiovascular disease, schizophrenia, and uterine leiomyoma. However, there is no evidence that C22orf23 is a direct therapeutic target, nor are there any known drugs, clinical biomarkers, or mechanism-of-action data associated with modulation of this protein.

Other names
C22orf23EVG1UPF0193 protein EVG1FLJ32787LOC84645dJ1039K5.6
02

Biological functions

Protein binding
03

Disease associations

Cancer (mutations found in ER+ breast cancer)Cardiovascular disease (epigenetic alterations found in coronary artery disease)Neurological disorders (implicated in demyelinating neuropathies, Waardenburg syndrome, Hirschsprung disease, and possibly schizophrenia)Uterine leiomyoma (dysregulated expression)

Beyond the preview

Go deeper on Chromosome 22 open reading frame 23 (C22orf23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromosome 22 open reading frame 23 (C22orf23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call